Patrick Hess
Overview
Explore the profile of Patrick Hess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, et al.
J Pharmacol Exp Ther
. 2019 Jan;
368(3):462-473.
PMID: 30622171
The endothelin (ET) system has emerged as a novel target for hypertension treatment where a medical need persists despite availability of several pharmacological classes, including renin angiotensin system (RAS) blockers....
2.
A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model
Seger S, Stritt M, Vezzali E, Nayler O, Hess P, Groenen P, et al.
PLoS One
. 2018 Mar;
13(3):e0193057.
PMID: 29547661
Intratracheal administration of bleomycin induces fibrosis in the lung, which is mainly assessed by histopathological grading that is subjective. Current literature highlights the need of reproducible and quantitative pulmonary fibrosis...
3.
Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al.
Pharmacol Res Perspect
. 2017 Dec;
5(6).
PMID: 29226621
Sphingosine-1-phosphate receptor 1 (S1P ) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P receptor...
4.
Rey M, Kramberg M, Hess P, Morrison K, Ernst R, Haag F, et al.
Pharmacol Res Perspect
. 2017 Aug;
5(5).
PMID: 28805949
The P2Y receptor is a validated target for prevention of major adverse cardiovascular events in patients with acute coronary syndrome. The aim of this study was to compare two direct-acting,...
5.
Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, et al.
J Pharmacol Exp Ther
. 2017 May;
362(1):186-199.
PMID: 28476928
Prostacyclin (PGI) receptor (IP receptor) agonists, which are indicated for the treatment of pulmonary arterial hypertension (PAH), increase cytosolic cAMP levels and thereby inhibit pulmonary vasoconstriction, pulmonary arterial smooth muscle...
6.
Surivet J, Zumbrunn C, Bruyere T, Bur D, Kohl C, Locher H, et al.
J Med Chem
. 2017 Apr;
60(9):3776-3794.
PMID: 28406300
There is an urgent unmet medical need for novel antibiotics that are effective against a broad range of bacterial species, especially multidrug resistant ones. Tetrahydropyran-based inhibitors of bacterial type II...
7.
Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser D, Hess P, et al.
J Pharmacol Exp Ther
. 2017 Feb;
361(2):322-333.
PMID: 28223322
Endothelin (ET) receptor antagonists have been associated with fluid retention. It has been suggested that, of the two endothelin receptor subtypes, ET receptors should not be blocked, because of their...
8.
Lescop C, Muller C, Mathys B, Birker M, de Kanter R, Kohl C, et al.
Eur J Med Chem
. 2016 Apr;
116:222-238.
PMID: 27061986
In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more...
9.
Bolli M, Lescop C, Birker M, de Kanter R, Hess P, Kohl C, et al.
Eur J Med Chem
. 2016 Mar;
115:326-41.
PMID: 27027817
In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is...
10.
Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, et al.
J Med Chem
. 2015 Nov;
58(23):9133-53.
PMID: 26550844
Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause...